Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug

April 24, 2026 11:03 AM EDTUpdated 11 hours ago News Briefing Ava­lyn plots $182M IPO; WHO pre­qual­i­fies No­var­tis' malar­ia drug ENDPOINTS Ava­lyn Phar­ma plots $182M IPO: The biotech, which is mak­ing in­haled ver­sions of ap­proved pul­monary fi­bro­sis med­i­cines, an­tic­i­pates about $182 mil­lion … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER